235 related articles for article (PubMed ID: 28290081)
1. Potential Use of MicroRNA for Monitoring Therapeutic Response to Antidepressants.
Belzeaux R; Lin R; Turecki G
CNS Drugs; 2017 Apr; 31(4):253-262. PubMed ID: 28290081
[TBL] [Abstract][Full Text] [Related]
2. Emerging role of microRNAs in major depressive disorder and its implication on diagnosis and therapeutic response.
Zhou L; Zhu Y; Chen W; Tang Y
J Affect Disord; 2021 May; 286():80-86. PubMed ID: 33714174
[TBL] [Abstract][Full Text] [Related]
3. Investigation of miR-1202, miR-135a, and miR-16 in Major Depressive Disorder and Antidepressant Response.
Fiori LM; Lopez JP; Richard-Devantoy S; Berlim M; Chachamovich E; Jollant F; Foster J; Rotzinger S; Kennedy SH; Turecki G
Int J Neuropsychopharmacol; 2017 Aug; 20(8):619-623. PubMed ID: 28520926
[TBL] [Abstract][Full Text] [Related]
4. Major depression and its treatment: microRNAs as peripheral biomarkers of diagnosis and treatment response.
Lopez JP; Kos A; Turecki G
Curr Opin Psychiatry; 2018 Jan; 31(1):7-16. PubMed ID: 29076893
[TBL] [Abstract][Full Text] [Related]
5. Criticisms of drugs in early development for the treatment of depression: what can be improved?
Wang SM; Han C; Pae CU
Expert Opin Investig Drugs; 2015 Apr; 24(4):445-53. PubMed ID: 25529224
[TBL] [Abstract][Full Text] [Related]
6. Amygdala Reactivity to Emotional Faces in the Prediction of General and Medication-Specific Responses to Antidepressant Treatment in the Randomized iSPOT-D Trial.
Williams LM; Korgaonkar MS; Song YC; Paton R; Eagles S; Goldstein-Piekarski A; Grieve SM; Harris AW; Usherwood T; Etkin A
Neuropsychopharmacology; 2015 Sep; 40(10):2398-408. PubMed ID: 25824424
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy with monoamine oxidase inhibitors and other antidepressants or stimulants: strategies for the management of treatment-resistant depression.
Thomas SJ; Shin M; McInnis MG; Bostwick JR
Pharmacotherapy; 2015 Apr; 35(4):433-49. PubMed ID: 25884531
[TBL] [Abstract][Full Text] [Related]
8. Alterations of microRNA-124 expression in peripheral blood mononuclear cells in pre- and post-treatment patients with major depressive disorder.
He S; Liu X; Jiang K; Peng D; Hong W; Fang Y; Qian Y; Yu S; Li H
J Psychiatr Res; 2016 Jul; 78():65-71. PubMed ID: 27078210
[TBL] [Abstract][Full Text] [Related]
9. Genome-wide microarray analysis of gene expression profiling in major depression and antidepressant therapy.
Lin E; Tsai SJ
Prog Neuropsychopharmacol Biol Psychiatry; 2016 Jan; 64():334-40. PubMed ID: 25708651
[TBL] [Abstract][Full Text] [Related]
10. [Depressive symptoms during anorexia nervosa: State of the art and consequences for an appropriate use of antidepressants].
Leblé N; Radon L; Rabot M; Godart N
Encephale; 2017 Feb; 43(1):62-68. PubMed ID: 27452149
[TBL] [Abstract][Full Text] [Related]
11. The role of circulating blood microRNA-374 and microRNA-10 levels in the pathogenesis and therapeutic mechanisms of major depressive disorder.
Liu W; Zhang F; Zheng Y; He S; Zhang T; Guo Q; Xu H; Chen H; Liu C; Yu S; Jiang K; Li H; Li G; Wang X; Liu X
Neurosci Lett; 2021 Oct; 763():136184. PubMed ID: 34418506
[TBL] [Abstract][Full Text] [Related]
12. miR-1202 is a primate-specific and brain-enriched microRNA involved in major depression and antidepressant treatment.
Lopez JP; Lim R; Cruceanu C; Crapper L; Fasano C; Labonte B; Maussion G; Yang JP; Yerko V; Vigneault E; El Mestikawy S; Mechawar N; Pavlidis P; Turecki G
Nat Med; 2014 Jul; 20(7):764-8. PubMed ID: 24908571
[TBL] [Abstract][Full Text] [Related]
13. microRNA-124: a putative therapeutic target and biomarker for major depression.
Dwivedi Y
Expert Opin Ther Targets; 2017 Jul; 21(7):653-656. PubMed ID: 28490207
[No Abstract] [Full Text] [Related]
14. Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited.
Prins J; Olivier B; Korte SM
Expert Opin Investig Drugs; 2011 Aug; 20(8):1107-30. PubMed ID: 21682663
[TBL] [Abstract][Full Text] [Related]
15. A brief review of antidepressant efficacy, effectiveness, indications, and usage for major depressive disorder.
Nierenberg AA; Ostacher MJ; Huffman JC; Ametrano RM; Fava M; Perlis RH
J Occup Environ Med; 2008 Apr; 50(4):428-36. PubMed ID: 18404015
[TBL] [Abstract][Full Text] [Related]
16. Inflammatory biomarkers as differential predictors of antidepressant response.
Hashimoto K
Int J Mol Sci; 2015 Apr; 16(4):7796-801. PubMed ID: 25856677
[TBL] [Abstract][Full Text] [Related]
17. Rational site-directed pharmacotherapy for major depressive disorder.
Blier P
Int J Neuropsychopharmacol; 2014 Jul; 17(7):997-1008. PubMed ID: 23745670
[TBL] [Abstract][Full Text] [Related]
18. The Antidepressant Treatment Response Index as a Predictor of Reboxetine Treatment Outcome in Major Depressive Disorder.
Caudill MM; Hunter AM; Cook IA; Leuchter AF
Clin EEG Neurosci; 2015 Oct; 46(4):277-84. PubMed ID: 25258429
[TBL] [Abstract][Full Text] [Related]
19. Circulating cytotoxic T cells and natural killer cells as potential predictors for antidepressant response in melancholic depression. Restoration of T regulatory cell populations after antidepressant therapy.
Grosse L; Carvalho LA; Birkenhager TK; Hoogendijk WJ; Kushner SA; Drexhage HA; Bergink V
Psychopharmacology (Berl); 2016 May; 233(9):1679-88. PubMed ID: 25953327
[TBL] [Abstract][Full Text] [Related]
20. Biomarkers predicting antidepressant treatment response: how can we advance the field?
Labermaier C; Masana M; Müller MB
Dis Markers; 2013; 35(1):23-31. PubMed ID: 24167346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
